Alzamend Neuro (NASDAQ:ALZN) Price Target Cut to $35.00 by Analysts at Ascendiant Capital Markets

Alzamend Neuro (NASDAQ:ALZN) had its price target decreased by Ascendiant Capital Markets from $50.00 to $35.00 in a research report sent to investors on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Alzamend Neuro Stock Up 0.7 %

ALZN stock opened at $1.50 on Monday. The business’s 50-day moving average is $1.73 and its two-hundred day moving average is $3.51. Alzamend Neuro has a 1 year low of $1.40 and a 1 year high of $19.20.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings results on Wednesday, September 11th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13. On average, equities research analysts predict that Alzamend Neuro will post -14.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC purchased a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro as of its most recent SEC filing. Hedge funds and other institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.